RGNT (Regentis Biomaterials) Book Value per Share: $0.92 (As of Dec. 2025)


RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $3.58
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials Book Value per Share?

Regentis Biomaterials RGNT 14 Book Value per Share is $0.92 as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Regentis Biomaterials's book value per share for the quarter that ended in Dec. 2025 was $0.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Regentis Biomaterials was -0.50% per year. The lowest was -9.10% per year. And the median was -4.80% per year.

Regentis Biomaterials's current price is $3.58. Its book value per share for the quarter that ended in Dec. 2025 was $0.92. Hence, today's PB Ratio of Regentis Biomaterials is 3.91.

During the past 6 years, the highest P/B Ratio of Regentis Biomaterials was 3.91. The lowest was 0.00. And the median was 0.00.


Regentis Biomaterials  (AMEX:RGNT) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Regentis Biomaterials Book Value per Share Related Terms


Regentis Biomaterials Book Value per Share Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials Book Value per Share Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial -8.21 -8.53 -9.31 -8.34 0.92

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -9.31 -7.85 -8.34 -8.99 0.92

RGNT vs HBIO, MLSS, RVP: Book Value per Share Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regentis Biomaterials PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's PB Ratio distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's PB Ratio falls into.


RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials Book Value per Share Calculation

Regentis Biomaterials's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.74-0.00)/5.18
=0.92

Regentis Biomaterials's Book Value Per Share for the quarter that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.74-0.00)/5.18
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $0.92 mean?
Regentis Biomaterials (RGNT) has a Book Value per Share of $0.92 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' Book Value per Share too high?
Regentis Biomaterials' current Book Value per Share is $0.92. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Book Value per Share compare to HBIO and MLSS?
Regentis Biomaterials' Book Value per Share of $0.92 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Devices & Instruments company?
A good Book Value per Share depends on the Medical Devices & Instruments industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Regentis Biomaterials and its competitors. Regentis Biomaterials's current Book Value per Share is $0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Book Value per Share of $0.92. The current Book Value per Share is $0.92. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Book Value per Share is $0.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.58
Price